Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 0.52% on January 19, 2025, underperforming the CSI 300 index by 0.57 percentage points, ranking 28th among 31 sub-industries [4]. - Notable performers within the pharmaceutical sub-industries included offline pharmacies (+2.39%) and blood products (+0.11%), while sectors such as medical R&D outsourcing (-1.77%) and vaccines (-1.10%) lagged behind [4]. - Takeda's new drug Oveporexton has received acceptance for its market application in China, targeting narcolepsy type 1 (NT1) and showing promising results in clinical trials [5]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceuticals: Neutral [3]

证券日报网讯 1月19日，天益医疗发布公告称，公司于近日收到国家药品监督管理局颁发的《医疗器械 注册证》，产品名称为一次性使用连续性肾脏替代治疗管路，注册证编号为国械注准20263100049，有 效期至2031年1月13日。 （文章来源：证券日报） ...

重要资讯 1. 国家统计局发布2025年国民经济数据，全年GDP突破140万亿元同比增长5%，制造业规模 有望连续16年保持全球第一，" 人工智能+"带动 存储芯片、 服务器产量分别增长22.8%、12.6%。 2. 美 国总统特朗普宣布对欧洲8国输美商品加征关税，引发国际 黄金、 白银价格创历史新高。 3. 工信部、 国家发改委等五部门联合印发意见，提出到2027年在汽车、 锂电池、 光伏等行业培育建设一批零碳工 厂。 4. 海南自贸港封关首月成效初显，新增外贸备案企业5132家，边检机关检查出入境人员、交通工 具同比分别增长31%、27%。 5. 2026年春运首日（2月2日）火车票1月19日开售，铁路部门推出误购票 限时免费退等新服务，预计中短途客流大幅增长。 公司资讯 1. 万科A及长沙市万科企业有限公司新增 一则10.8亿余元的被执行人信息。 2. 隆基绿能发布2025年度业绩预告，预计净亏损60-65亿元，BC二代 产品顺利规模化量产并正式进军 储能领域。 3. 万华化学于1月16日在山东莱州成立注册资本7.4亿元的 万华化学集团（莱州） 新能源材料科技有限公司。 4. 智元 机器人与 蓝思科技、 ...

Group 1 - Tianyi Medical has received a medical device registration certificate from the National Medical Products Administration for a disposable continuous renal replacement therapy circuit, which is a complete and integrated extracorporeal circulation system designed to meet clinical operational and safety needs in intensive care settings, compatible with the Nikkiso Aquarius blood purification device [1] Group 2 - Jinchong Co., Ltd. has announced that January 19 is the last conversion day for "Jinchong Convertible Bonds," and investors holding these bonds can convert them before market close on that day; after this date, unconverted bonds will be forcibly redeemed at a price of 100.2 yuan per bond, potentially leading to losses for investors [2] Group 3 - Beixin Building Materials has completed the payment of the principal and interest for the second phase of its ultra-short-term financing bonds for the year 2025, totaling 1.007 billion yuan, which has been transferred to the designated accounts of bondholders by the China Interbank Market Clearing House [3]

天益医疗（301097）(301097.SZ)发布公告，公司于近日收到国家药品监督管理局颁发的《医疗器械注 册证》，产品名称：一次性使用连续性肾脏替代治疗管路。 本次获得注册证的一次性使用连续性肾脏替代治疗管路，是一套完整集成、专业可靠的体外循环管路系 统，其高度集成的多管路设计与完备的安全配件，能够更好地满足重症监护环境下连续性肾脏替代治疗 的临床操作与安全需求，适配于日机装Aquarius血液净化设备。本次获得注册证书，为公司相关产品注 册证书的顺利展期，证明公司产品持续符合相关监管要求，对巩固和扩大市场竞争力具有积极意义。 ...

21智讯1月19日电，天益医疗公告，公司收到国家药品监督管理局签发的一次性使用连续性肾脏替代治 疗管路《医疗器械注册证》。该产品用于与AQUARIUS系列连续性血液净化装置和连续性肾脏替代专 用滤器配套使用，提供连续性肾脏替代治疗缓慢连续超滤SCUF、连续性静-静脉血液滤过CVVH、连续 性静-静脉血液透析CVVHD、连续性静-静脉血液透析滤过CVVHDF、治疗性血浆置换TPE、血液灌流 HP，承担血液及液体通路的功能。 ...

本次获得注册证的一次性使用连续性肾脏替代治疗管路，是一套完整集成、专业可靠的体外循环管路系 统，其高度集成的多管路设计与完备的安全配件，能够更好地满足重症监护环境下连续性肾脏替代治疗 的临床操作与安全需求，适配于日机装Aquarius血液净化设备。本次获得注册证书，为公司相关产品注 册证书的顺利展期，证明公司产品持续符合相关监管要求，对巩固和扩大市场竞争力具有积极意义。 智通财经APP讯，天益医疗(301097.SZ)发布公告，公司于近日收到国家药品监督管理局颁发的《医疗器 械注册证》，产品名称：一次性使用连续性肾脏替代治疗管路。 ...

Group 1 - Kangfang Biotech's PD-1/CTLA-4 bispecific antibody KAITENI® has received approval for a new indication in the treatment of cervical cancer, marking the third indication for this drug [1] - Tianyi Medical has obtained product registration certificates for single-use continuous renal replacement therapy tubing and single-use hemodialysis tubing, both sterilized with ethylene oxide [2] - Jincheng Pharmaceutical's posaconazole enteric-coated tablets and injectable cefoperazone sodium have been approved, enhancing the company's competitiveness in the antifungal and anti-infection sectors [3] Group 2 - Prolo Pharma has received approval for the raw material drug succinate desvenlafaxine, expanding its product pipeline in the antidepressant treatment field [4] - Wantai Biological Pharmacy's first domestically produced nine-valent HPV vaccine has been approved, with approximately 1 billion yuan invested in research and development as of May 2025 [5] - Yuheng Pharmaceutical's subsidiary has signed a market promotion service agreement with Eisai (China) Pharmaceutical for the exclusive promotion of mecobalamin injection, which is used for peripheral neuropathy and vitamin B12 deficiency-related anemia [6]